Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),...
News
Medigene Announces U.S. FDA Clearance of IND Application for MDG1015, a First-in-Class, Third Generation T Cell Receptor Engineered T Cell (TCR-T) Therapy for Multiple Solid Tumor Indications
Planegg/Martinsried, September 5, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on...
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BRISBANE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted...
Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its...
Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
BASKING RIDGE, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Fort Lee, NJ, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage...
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated...
Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification
Curated data show expression of PDE4B above a specific measurable threshold observed in 70% of adult colitis patients and 90%...
4DMT Announces Presentations at Upcoming Retina Conferences
EMERYVILLE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage...
Myriad Genetics to Host Investor Event on October 9, 2024
SALT LAKE CITY, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and...
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
ARQ-255 is a topical Janus kinase 1 (JAK1) inhibitor suspension formulated as a potential topical treatment for alopecia areataProprietary Deep...
Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial...
Alignment Health Named One of Newsweek’s World’s Most Trustworthy Companies in 2024
ORANGE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Alignment Health, a consumer brand name of Alignment Healthcare, Inc. (NASDAQ: ALHC),...
Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference
WALTHAM, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
Eccogene Appoints Glenn Reicin as Chief Financial Officer
BOSTON, Mass. and SHANGHAI, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule...
Exyte acquires TTP Group to accelerate growth of Biopharma and Life Sciences business
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industryThe company serves blue-chip clients in Europe TTP Group...
IKA introduces new accessories for HABITAT research bioreactor
More options for smoother bioprocessing workflows and greater data reliability STAUFEN, Germany, Sept. 5, 2024 /PRNewswire/ -- IKA, a global company in...
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration
NANJING, China, Sept. 5, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets...
Bioz Founders Share Vision for Transforming Research Efficiency, Highlighting Commitment to Empowering Scientists
PALO ALTO, CA / ACCESSWIRE / September 5, 2024 / Bioz, Inc., a leader in AI-driven research efficiency solutions, is...
Modular Medical Announces Conference Call to Discuss FDA Clearance of the MODD1 Insulin Pump
SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an...